Zymeworks BC Inc [ZYME] stock is trading at $14.76, up 11.14%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ZYME shares have gain 11.48% over the last week, with a monthly amount glided 17.42%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zymeworks BC Inc [NASDAQ: ZYME] stock has seen the most recent analyst activity on November 01, 2024, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $12 for it. On January 04, 2023, H.C. Wainwright reiterated its Neutral rating and revised its price target to $8 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $11 on December 20, 2022. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $8 on November 01, 2022. SVB Leerink downgraded its rating to Mkt Perform for this stock on October 21, 2022, but kept the price target unchanged to $8.
Zymeworks BC Inc [ZYME] stock has fluctuated between $6.83 and $14.05 over the past year. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $14.76 at the most recent close of the market. An investor can expect a potential return of 15.18% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 62.20M for the trailing twelve months, which represents a drop of -3.07%. Gross Profit Margin for this corporation currently stands at -0.02% with Operating Profit Margin at -551.32%, Pretax Profit Margin comes in at -477.7%, and Net Profit Margin reading is -481.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.33 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.62 points at the first support level, and at 12.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.45, and for the 2nd resistance point, it is at 16.14.
Ratios To Look Out For
For context, Zymeworks BC Inc’s Current Ratio is 4.10. As well, the Quick Ratio is 4.10, while the Cash Ratio is 1.46. Considering the valuation of this stock, the price to sales ratio is 15.97, the price to book ratio is 2.82.
Transactions by insiders
Recent insider trading involved Galbraith Kenneth, Chair & CEO, that happened on Jan 05 ’24 when 18198.0 shares were sold. Chair & CEO, Galbraith Kenneth completed a deal on Jan 08 ’24 to sell 5706.0 shares. Meanwhile, SVP & Chief Financial Officer Astle Christopher sold 4563.0 shares on Jan 05 ’24.
